This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Nyxoah SA
11/5/2026
Good day and thank you for standing by. Welcome to the NCSOA third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pearson Dennis, Investor Relations Associate. Please go ahead.
Thank you. Good afternoon, everyone, and I welcome you to our third quarter 2026 earnings call. Participating from the company today will be Liam Kelly, President and Chief Executive Officer, and Loic Moreau, Interim Chief Financial Officer. During the call, we will discuss our operating activities and review our third quarter 2026 financial results released after US market closing today, after which we will host a question and answer session. The press release can be found on the investor relations section of our website. This call is being recorded and will be archived in the events section on the investor relations tab of our website. Before we begin, I'd like to remind you that any statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these forward-looking statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors section of our form 20F, which was filed with the Securities and Exchange Commission on March 26, 2026. With that, I will now turn the call over to Liam. Thank you, Pearson.
Good afternoon, everyone, and thank you for joining us. This is my first earnings call as president and chief executive officer, and I am very pleased to be with you today. For those of you I have not yet met, let me briefly introduce myself. I bring more than 25 years of leadership experience in the medical technology industry, with a strong focus on commercial execution in the US and international markets. During my time at Teleflex, I executed on significant product launches and expansions. These include products like Easy IO, OnControl, Guideliner, Trapliner, Turnpike, Eurolift, Manta, Barigel, and EasyPlaz. Many of these products are now the standard of care in their treatment modality. I also worked alongside a talented team to grow revenues, expand both growth and operating margins, and drive shareholder value. Let me begin by thanking Olivier Taelman for his leadership over the past seven years. Olivier guided Nixoa from clinical development through FDA approval and into our US commercial launch. The foundation he and the team built is a large part of what drew me to this company. I'm excited to join Nixoa at this pivotal stage in the company's development for three primary reasons. First, Geneo is a meaningfully differentiated therapy. Second, obstructive sleep apnea is a large and under-penetrated market. And third, we have a dedicated team that is capable of executing on our opportunity. I have had an excellent start to my time at Nixos. I've spent the last few weeks learning about the Geneo product and its clinical differentiation, reviewing our go-to-market strategy, Spending time with some key members of the team and meeting some of our key customers to hear their perspective. While it's still early in my onboarding process, a couple of things are clear. First, our employees are excellent. They are dedicated, driven, knowledgeable, and above all, patient-focused. They are eager to make Genio a successful product globally. They don't just want to be part of a great company, They want to help build a great company. Second, the Genio product is truly differentiated from the competition. It is the only bilateral HGNS therapy on the market. Our PMA submission, if approved, will not only allow us to serve more patients with complete concentric collapse, but will also significantly streamline the patient journey. CCC patients account for about one in four of the patients evaluated for this therapy and have no hyperglossal nerve stimulation option today in the United States. Third, we are executing well in our commercial launch in the US. We have seen robust performance for a new product launch and this is evidenced in our revenue trajectory. In addition, we continue to execute well in international markets. While I am still early in my new role, three short to medium term objectives are beginning to emerge. Number one is to refocus NYXOA from an R&D and clinical development organization to a commercially centric organization. Number two is continuing to invest to drive penetration in the US market while maintaining solid growth internationally. and number three is to continue to expand our gross margins and manage our operating expenses prudently. In summary, I believe there is substantial opportunity ahead for Nixoa and that we have the right team to deliver the expected results as we work together to build a great company. Now, let me turn to a high level overview of the third quarter. U.S. net revenue was €6.7 million, representing 29% sequential revenue growth. This is an acceleration from the 22% growth we achieved in the second quarter. Global net revenue was €9.2 million, up 19% sequentially, and our international business continues to perform in line with our expectations. As we announced on October 19, We pre-announced revenue for the quarter and adjusted our full year 2026 revenue guidance to a range of €33 million to €35 million. While we are disappointed to adjust our guidance, we are proud of the strong start to our commercial launch and acceleration in growth. The new guidance is based on US revenues that are more reflective of historical ramps for a new technology. as physicians and centers build experience with Genio. As I step into the role, I want to clarify that it is not our intent to systematically pre-announce our revenue on a quarterly basis. Despite the change in guidance, our foundations are strong. Physicians and OSA patients want a choice in hypoglossal nerve stimulation therapy. Genio is a differentiated product and this has led to the growing number of trained surgeons and active accounts in the United States as well as positive feedback we received on the Genio system. Our access results and our PMA supplement submission could extend our differentiation in complete concentric collapse patients in the United States. The US launch remains the primary driver of our growth and our top priority. Our US key performance indicators as of September 30th, 2026 were strong. We trained 80 new surgeons in Q3, bringing the total to 342 surgeons trained on the Genio system. We activated 53 new accounts in Quarter 3, bringing the total to 233 active Genio accounts. We had 447 patients actively undergoing prior authorization in our GenioAccess program entering the fourth quarter of 2026. We continue to execute a focused launch. Today, we have 55 sales reps with 233 active accounts at the end of the third quarter. We will, of course, continue to activate new accounts Train New Surgeons, but our focus on driving growth will be to go deeper in our existing accounts and drive utilization. Now for a reimbursement update. Our CMS and commercial payer coverage remain broad and stable and our market access team continues to execute well on prior authorization submissions. In addition, CMS has published its final rule on 2027 reimbursement for the Genio procedure. Hospital outpatient reimbursement under C code C8011 increases from $31,526 to $35,072 or approximately 11%. Ambulatory surgical center reimbursement increases from $27,563 to $31,283 or approximately 13%. The facility increases strengthen the economic value of the Genio procedure. Clinical and regulatory progress was another highlight of the quarter. In September, we announced that our ACCESS US Pivotal Study met its co-primary efficacy endpoints and its safety endpoints in patients with complete concentric collapse, or CCC. At 12 months, the Apnea Hypopnea Index, or AHI, responder rate was 77.2%, and the ODI responder rate was 87.7%, both highly statistically significant. with zero device and procedure related serious adverse events. The complete 12-month data set was presented at the International Surgical Sleep Society annual meeting on October 15th and 16th. CCC patients are currently contraindicated for commercially available unilateral hypoglossal nerve stimulation in the United States. These OSA patients have limited treatment options today. Genio has been approved for CCC patients in Europe since 2021 and we have now submitted a pre-market approval or PMA supplement to the FDA to expand Genio's US indication to include CCC patients. We have initiated a US post-approval study called BREATHE focused on building long-term real-world evidence for bilateral hypoglossal nerve stimulation in routine clinical practice. Now for an international update. We continue to execute in our focused markets with a disciplined approach. International revenue grew 42% compared to the third quarter of 2025. With that, I will now turn the call over to Loic for a detailed review of our financial results. Loic. Thank you, Liam.
You're reading a preview of the NYXH Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing